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Introduction: Senticol 2 is a randomized multicenter trial in the treatment of early-stage
cervical cancer patients. The aim of the Senticol 2 study was to compare the effect of
sentinel-lymph-node biopsy (SLNB) to that of SLNB + pelvic lymphadenectomy (PLND),
and to determine the postoperative lymphatic morbidity in the two groups. Here, we report
a secondary objective of this study: the follow up.
Material and Methods: In the Senticol 2 trial, patients underwent a laparoscopy with a
sentinel-node-detection procedure and were randomized into two groups, namely: Group
A, in which participants received SLNB, and Group B, in which participants received
SLNB + PLND. Patients with an intra-operative macroscopically suspicious lymph node,
were given a frozen-section evaluation and were randomized only if the results were
negative. All of the patients received follow up with a clinical examination at 1, 3, and 6
months after surgery, and then every 3–4 months after that. The median follow up was 51
months (4 years and 3 months).
Results: Disease-free survival after 4 years for the SLNB group and the SLNB + PLND
group were 89.51% and 93.1% (p = 0.53), respectively. The only statistical factor
associated with recurrence in the univariate analysis was the adjuvant radiotherapy. No
other factors, including the age of the patients, histological type, tumor size, lymph
vascular space invasion (LVSI), and positive nodal status, were significant in the univariate
or multivariate analyses. The overall survival rates after 4 years in the SLNB and SLNB +
PLND groups were 95.2% and 96% (p = 0.97), with five and four deaths, respectively. The
univariate and multivariate analyses did not find any prognostic factors.
Conclusions: This randomized study confirmed the results of the Senticol 1 study and
supports the sentinel lymph node (SLN) technique as a safe technique for use in patients
with early-stage cervical cancer treated with SLNB only. Disease-free survival after 4 yearsFebruary 2021 | Volume 10 | Article 6215181
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lymphadenectomy.Keywords: cervical cancer, sentinel lymph node, lymphadenectomy, survival, lymph node biopsyINTRODUCTION
Cervical cancer results in over 300,000 deaths worldwide every
year (1).
Advances in cervical-cancer screening have resulted in a
lower incidence of cervical cancer but a higher incidence of
early-stage disease diagnosis in developed countries (2, 3). One of
the most important prognosis factors in the early stages is the
pelvic lymph-node status.
It has been demonstrated that the lymph-node status directly
impacts the 5-year survival rate of patients with International
Federation of Gynecology and Obstetrics (FIGO 2009) Stage IA1
to IIB cancers (4).
According to the international guidelines for the treatment of
early-stage cervical cancer, the gold-standard treatment includes
pelvic-lymph-node dissection (PLND) in order to adapt the
treatment to a potential lymphatic metastasis. In the Senticol 1
trial (5), we demonstrated the feasibility and safety of the sentinel
lymph node (SLN) technique when used with bilateral detection.
A review of the literature by Tax et al. showed 99% sensitivity
and a 97–100% negative predictive value (NPV) for the
bilaterally detected sentinel lymph node (SLN) technique (3).
A lymph-node metastasis is present in 27% of early cervical
cancers, leading to a high rate of overtreatment with unnecessary
PLND in three out of four patients (2, 3). Moreover, this
lymphatic surgery is known to induce significant morbidity
and to lead to a decreased quality of life (6).
A SLNB procedure can accurately detect metastases for
several other diseases such as breast, penile, skin, and vulvar
cancer. In 2015, the National Comprehensive Cancer Network
(NCCN) Guidelines (7) stated that SLN mapping should be
considered an option for PLND in cervical cancer (category 2B).
Furthermore, we showed previously that an SLN biopsy can
decrease both early and long-term morbidity and can improve
quality of life comparedwith a complete pelvic lymphadenectomy (6).
The aim of this study was to assess the disease-free survival
and overall survival of early-stage cervical cancer patients
included in the randomized controlled multicenter Senticol
2 study.PATIENTS AND METHODS
Patients
The Senticol 2 protocol (clinical trial #NCT01639820) was
approved by an ethics committee (Comité de Protection des
Personnes Sud-Est IV, decision A08-223) and all of the patients
provided written informed consent before inclusion.
We performed a randomized controlled trial from December
2008 to November 2011. A total of 25 centers were included, all2
surgical team were experimented (>20 cases). The number of
cases per center and the name of the surgeon is described in
Supplementary Table 2 in the Appendix.
Patients were followed for a minimum of 3 years after their
inclusion in the study.
The inclusion criteria were as follows: Women aged 18 or
older diagnosed with cervical carcinoma of FIGO 2009 stage IA1
with LVSI, to IIA1, including any histological subtype (except
neuroendocrine carcinoma). The patients were eligible for
laparoscopy and written informed consent was obtained from
all of the patients.
The exclusion criteria were as follows: Pregnant women, stage
IB (by downstaging), evolving or recurrent cervical cancer, other
cancer diagnosed during treatment, history of pelvic node
surgery, or severe allergy or contraindication to radioactive
tracer or Patent Blue.
Methods
All patients received injections of the radioactive tracer colloidal
rhenium sulfide labeled with technetium (99mTc; Nanocis®, CIS
Bio International) on the day of (60 MBq; short protocol) or the
day before the surgery (120 MBq; long protocol), after which 2
mL of vital dye (Patent Blue®, Laboratoire Guerbet) diluted with
2 mL of water was injected into the cervix at the 3, 6, 9, and 12
o’clock positions.
In addition, a pre-operative lymphoscintigraphy was
performed in order to detect SLNs during surgery, especially in
unexpected locations.
The patients underwent a laparoscopy using a sentinel-node-
detection procedure and were randomized into the following two
groups: Group A, which received sentinel lymph node biopsy
(SLNB), and Group B, which received SLNB + PLND.
The patients with intra-operative macroscopically suspicious
sentinel or eventually non sentinel lymph nodes (NSLNs)
received a frozen-section evaluation and were randomized only
if the results were negative.
All of the SLNs were analyzed using the histological
ultrastaging method (200 µm sections) and were stained with
hematoxylin eosin saffron (HES) or hematoxylin phloxine
saffron (HPS). An additional immunohistochemistry (IHC)
analysis with a pan-cytokeratine antibody was performed in
case of a negative SLN.
For the definite node-negative patients, we proceeded with an
additional surgery—either a radical hysterectomy or radical
trachelectomy (an extrafascial hysterectomy or simple
trachelectomy were performed for tumors <2cm without lymph
vascular space invasion (LVSI)). Adjuvant treatments were
defined following the final histology.
For the definite node-positive patients, we proceeded with an
additional treatment using chemo-radiotherapy after first
considering a laparoscopic para-aortic lymphadenectomy.February 2021 | Volume 10 | Article 621518
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3, and 6 months after surgery, and then every 3–4 months
afterwards. The median follow-up duration was 51 months.
Statistical Methods
Disease-free survival rates were estimated using the Kaplan
Meier method. The survival curves were compared with a Log-
rank test (unilateral test with a 5% significant threshold).
Recurrence-free survival was defined as the time from surgery
to disease recurrence or death due to any cause. A second
analysis regarding patients with no evidence of recurrence or
death was done at the date of the last follow-up. A multivariate
analysis was performed including factors with p < 0.15. The
multivariate analysis of the recurrence-free survival was
performed using a Cox’s proportional hazard model. All of the
analyses were performed on an intention-to-treat basis.RESULTS
Characteristics of Patients
Between December 2008 and November 2011, 267 patients
participated in Senticol 2. Of these, 61 patients were excluded
—2 (3.3%) had not had a lymphoscintigraphy before surgery,
12 (19.7%) had an incomplete SLNB procedure, 11 (18%)
had an absence of SLN detection, 21 (34.4%) had a unilateral
detection of SLN, and 15 (24.6%) had positive SLN on the
frozen sections.
A total of 206 patients were randomized, with 105 patients
assigned to Group A (SLNB) and 101 to Group B
(SLNB + PLND).
The baseline characteristics of the patients at inclusion are
summarized in Table 1. The median ages were 42.2 and 41.7
years, respectively. Most patients (88.4%) had FIGO stage IB
disease. Histological subtypes represented were mainly
epidermoid carcinoma (64.8% and 72.3%, respectively). There
was a nonsignificant difference between the two groups in terms
of the size of the tumors (median sizes were 19 and
15 mm, respectively).
All patients received injections of the 96 technetium and 2 mL
of vital dye (Patent Blue®) diluted with 2 mL of water injected
into the cervix at the 3, 6, 9, and 12 o’clock positions. We had no
cases with discrepancy between the lymph-nodes marked with
patent blue and lymph-nodes marked with technecium. During
the SLN procedure, there was no difference in sentinel mapping
between the two groups (Supplementary Table 1 in the
Appendix). The main location for the sentinel node was ilio-
obturator and external iliac area (85.8%). The second main
location was the common iliac area (9.6%) of SLN.
The surgical approaches were similar in the two groups
(p = n.s.), with a radical hysterectomy rate of 78.7% and
80.5%, a radical trachelectomy rate of 16.9% and 13.4%, and a
simple hysterectomy and trachelectomy rate of 4.5% and
6.1%, respectively.
The final histological analysis (including ultrastaging) of the
SLNs indicated 12 (11.4%) patients with a positive node in theFrontiers in Oncology | www.frontiersin.org 3SLNB group (three with macro-metastasis, three with micro-
metastasis, and six with isolated tumor cells) and 9 (8.9%)
patients with a positive node in the SLNB + PLND group
(three with macro-metastasis, four with micro-metastasis, and
two with isolated tumor cells) (p = n.s.). In this group there were
9 positive SLN and 1 positive NSLN in a patient with a positive
SLN also. The correspondence between SLN and NSLN
was 100%.
The rate of postoperative adjuvant therapy was similar in the
two groups (Table 2), including brachytherapy (32 in the SLNB
group and 27 in the SLNB + PLND group), radiotherapy (13 and
16, respectively), and chemotherapy (9 and 11, respectively).
Nine patients from the SLNB group underwent a secondary
lymph-node dissection in raison of positive SLN on the final
pathology. This secondary dissection was performed according to
the protocols of the different centers. One patient had only a pelvic
lymphadenectomy, 6 patients had pelvic and para-aortic dissection,






Age (median) 42.2 41.7 0.81
BMI (median) 22.7 22.6 0.92












History of pregnancy (n (%)) 85 (81) 87 (86.1) 0.43
Menopausal status (n (%)) 29 (28.2) 30 (30)
FIGO 2009 stage at inclusion



























Preoperative conization (n (%))

















0.87February 2021 | Volume 10 | ArticleSLNB, sentinel lymph node biopsy; PLND, pelvic lymph node dissection; BMI, body mass
index; PS, performance status; LVSI, lymph vascular space invasion.TABLE 2 | Post-operative adjuvant therapy.












0.64SLNB, sentinel-lymph-node biopsy; PLND, pelvic lymph-node dissection.621518
Favre et al. The Follow-Up of Senticol 2case of positive para-aortic node in a patient with micrometastasis
in the SLN, and one patient with 2 pelvic positive nodes on the
secondary pelvic lymphadenectomy after metastatic SLN.
Survival Outcomes
The mean follow-up duration was 50 months (3–89 months),
with a median of 51 months (4 years and 3 months).
Disease-free survival after 4 years in the SLNB and SLNB +
PLND groups was 89.5% and 93.1% (p 161 = 0.53), respectively.
There was no significant difference between the two groups.
There were 11 recurrences in the SLNB group and 7 in the
SLNB + PLND group (Figure 1). The most statistically
significant factor identified in the univariate analysis was
radiotherapy. In fact, we observed 11 recurrences in the patients
treated with adjuvant radiotherapy (15.5%). Other factors that
influenced disease-free survival after 4 years in the univariate and
multivariate analyses included the age of the patients, histological
type, tumor size, presence of LVSI, positive nodal status, surgical
approach, and adjuvant treatment. However, a trend was
observed, depending on the case, for LVSI. In the multivariate
analysis, both of these covariates (LVSI and adjuvant
radiotherapy) were significant (Table 3). The type of recurrences
is described in Table 4; there were 2 lymphatic recurrences: one
pelvic in the SLNB group and one para-aortic (associated with
liver metastasis) in the SLNB + PLND group.
During the follow-up period, nine deaths were observed (four
in the SLNB + PLND group and five in the SLNB group). TheFrontiers in Oncology | www.frontiersin.org 4overall survival (OS) for the patients who received SLNB was
95.2, and 96% for those who received SLNB + PLND (p = 0.97).
In the univariate analysis, none of the risk-factor covariates that
were analyzed were statistically significant for any of the clinical
events at a p = 0.05 level. However, a trend could be observed,
depending on the case, for the covariates—namely adjuvant
radiotherapy and LVSI. When we retained covariates with a
p-value of <0.15 in the univariate analysis in a multivariate
model, none were statistically significant (Table 5).DISCUSSION
Full pelvic lymph-node dissection is associated with early and
long-term morbidity. Limited dissection of SLNB is associated
with lower morbidity and a better quality of life (6).
Moreover, the SLN procedure has been intensely assessed,
and has shown safe and relevant results as follows: considering
bilateral SLN detection with histological ultrastaging, a 99–100%
sensitivity with a 97–100% NPV was demonstrated (3). While
this technique has been used in tumors up to 4 cm in size,
the best detection rates and mapping results are in tumors less
than 2 cm (7). The ultrastaging techniques, combining serial
sectioning and IHC, improved the rate of nodal metastasis
detection and revealed that 8.1% of apparently node-negative
patients were classified as node-positive. Low-volume metastasis
(micrometastasis and isolated tumor cells) is usually onlyFIGURE 1 | Disease-free survival rate at 4 years.February 2021 | Volume 10 | Article 621518
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being debated. The FIGO 2018 (8) classification considers only
macro- and micro-metastases to be significant lymph-node
metastases; the presence of isolated tumor cells does not
change the stage. Our recent study, presented at the ASCO
2020 Congress (9) and recently published (10), demonstrated
that the sentinel-node technique is reliable even from the point of
view of low-volume metastasis in NSLN. The limitation of the
ultrastaging technique is that it cannot be performed
intraoperatively as it is too cumbersome and time-consuming.
Considering the convenience of a single-step approach in early
stage cervical cancer, the one-step nucleic acid amplification
(OSNA) assay has recently been investigated in several tumor
types, including cervical cancer patients (11). More important
results are expected on the study of this technique in cervical
cancer in order to be able to draw conclusions about
its reliability.
In our study, the results showed that for women with early-
stage cervical cancer from FIGO (2009) IA1 to IIA1, the SLN
procedure alone did not result in a significant disease recurrence
compared to complete pelvic lymph-node dissection. In addition,
no significant difference was found in the overall survival
between the two groups.Frontiers in Oncology | www.frontiersin.org 5Considering that a great majority of recurrences normally
appear within 3 years after treatment, SLNB seems to be a safe
and efficient alternative to lymphadenectomy, and should be
proposed to every patient as a routine protocol for early-stage
cervical cancer in cancer centers where surgeons are familiar
with this technique and follow the correct SLN protocol. It
should still be considered that the study was not designed to
compare the survival and the risk of recurrence between the two
groups (SLNB and SLNB + PLND). This subgroup of patients
with early-stage cervical cancer indeed had a good survival with a
low recurrence rate. In conclusion, too few events were observed
during long-term follow up (4 years) to allow for a tangible
analysis of the risk factors for survival or disease-free survival.
However, this was the first randomized controlled prospective
study evaluating the follow up of SLNB alone in comparison with
SLNB + PLND, and it confirmed the Senticol 1 results.
Considering the other factors associated with risk of
recurrence, only the adjuvant radiotherapy was statistically
significant (p = 0.02). This result can be explained by the fact
that the patients who presented major risk criteria (according to
the Seidlis criteria) (12) were treated with radiotherapy. In the
multivariate analysis, no factors were significant for either the
risk of recurrence or for survival.
Recently, the LACC study by Pedro Ramirez (13) demonstrated
the superiority of open surgery for better survival and disease-free
survival in the treatment of early-stage cervical cancer. Our study
was designed before Ramirez’s study, and the vast majority of our
patients were operated on via laparoscopy. Open surgery was
performed only in the case of complications during laparoscopic
surgery. It is interesting that in our study, we found a survival andTABLE 4 | Type of recurrences.
Group Recurrence Time of recurrence Death
SLNB Lungs 18 months Yes
SLNB Lungs 14 months No
SLNB Parametrium 15 months Yes
SLNB Lungs 49 months No
SLNB Pelvic 19 months Yes
SLNB Inguinal 49 months No
SLNB Lymphatic (right iliac) 52 months No
SLNB Vaginal 9 months Yes
SLNB Liver 26 months Yes
SLNB Peritoneum 30 months No
SLNB Vaginal 30 months No
SLNB +
PLND
Carcinosis and lungs 50 months Yes
SLNB +
PLND
Parametrial 72 months No
SLNB +
PLND
Lungs 17 months Yes
SLNB +
PLND








Vaginal 28 months No
SLNB +
PLND
Peritoneum 31 months NoFebruary 2021 | Volume 10 | ArticleSLNB, sentinel lymph node biopsy; SLNB+PLND, sentinel lymph node biopsy + pelvic
lymphadenectomy.TABLE 3 | Univariate and multivariate analyses of the association between










Squamous 135 12 (8.9%)
Adenocarcinoma 56 5 (8.9%)
Adenosquamous 6 1 (16.7%)
Other 9 0
Tumor size 0.92
<2 cm 28 2 (7.2%)




Yes 21 2 (9.5%)
No 185 16 (8.6%)
Type of surgery 0.97













Type B 158 10 (6.3%)




Pos 48 7 (14.9%)




Yes 71 11 (15.5%)
No 135 7 (5.2%)621518
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Ramirez’s study. This comparison is limited, as our study was
designed for laparoscopic treatment and there were a large number
of cases where the colpotomy was performed vaginally with
protective measures. A vaginal colpotomy may protect from the
risk of tumor dissemination and recurrence (14).CONCLUSIONS
SLN biopsy was found to be a safe technique allowing for
accurate nodal staging in early cervical cancer.
Furthermore, this surgery led to less morbidity and to a
clearly improved quality of life for patients. Given that disease
recurrence after 4 years was similar in patients who underwentFrontiers in Oncology | www.frontiersin.org 6an SLN procedure, this study strongly supports the extension of
this surgical approach to all clinically node-negative patients
(cN0) affected by early cervical cancer.
A strong and influential study called Senticol 3 (15) and
SentiX (16) is under way in order to confirm the equivalent
survival in SLNB and SLNB + PLND patients.DATA AVAILABILITY STATEMENT
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